Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.2% – Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) traded down 4.2% during mid-day trading on Tuesday . The stock traded as low as $11.88 and last traded at $11.87. 129,341 shares changed hands during trading, a decline of 90% from the average session volume of 1,352,046 shares. The stock had previously closed at $12.39.

Wall Street Analyst Weigh In

DYN has been the subject of several research analyst reports. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. BMO Capital Markets started coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 17th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Robert W. Baird initiated coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.46.

Dyne Therapeutics Price Performance

The company has a market cap of $1.30 billion, a PE ratio of -3.23 and a beta of 1.11. The company’s fifty day moving average price is $13.54 and its 200 day moving average price is $23.99.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 6,237 shares of company stock worth $77,760 over the last three months. 20.77% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the 3rd quarter valued at about $36,000. GF Fund Management CO. LTD. purchased a new stake in Dyne Therapeutics during the fourth quarter valued at about $50,000. KBC Group NV boosted its position in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. Finally, Quest Partners LLC increased its stake in shares of Dyne Therapeutics by 898.3% in the third quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock worth $123,000 after purchasing an additional 3,090 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.